|
1
|
Ossenkoppele GJ, Graveland WJ, Sonneveld
P, Daenen SM, Biesma DH, Verdonck LF, Schaafsma MR, Westveer PH,
Peters GJ, Noordhuis P, Muus P, Selleslag D, van der Holt B,
Delforge M, Lowenberg B and Verhoef GE: The value of fludarabine in
addition to ARA-C and G-CSF in the treatment of patients with
high-risk myelodysplastic syndromes and AML in elderly patients.
Blood. 103:2908–2913. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Faderl S, Gandhi V, O’Brien S, Bonate P,
Cortes J, Estey E, Beran M, Wierda W, Garcia-Manero G, Ferrajoli A,
Estrov Z, Giles FJ, Du M, Kwari M, Keating M, Plunkett W and
Kantarjian H: Results of a phase 1–2 study of clofarabine in
combination with cytarabine (ara-C) in relapsed and refractory
acute leukemias. Blood. 105:940–947. 2005.
|
|
3
|
Fiedler W, Serve H, Döhner H, Schwittay M,
Ottmann OG, O’Farrell AM, Bello CL, Allred R, Manning WC,
Cherrington JM, Louie SG, Hong W, Brega NM, Massimini G, Scigalla
P, Berdel WE and Hossfeld DK: A phase 1 study of SU11248 in the
treatment of patients with refractory or resistant acute myeloid
leukemia (AML) or not amenable to conventional therapy for the
disease. Blood. 105:986–993. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Niitsu N, Yamamoto-Yamaguchi Y, Kasukabe
T, Okabe-Kado J, Umeda M and Honma Y: Antileukemic efficacy of
2-deoxycoformycin in monocytic leukemia cells. Blood. 96:1512–1516.
2000.PubMed/NCBI
|
|
5
|
Tallman MS, Kim HT, Paietta E, Bennett JM,
Dewald G, Cassileth PA, Wiernik PH and Rowe JM: Acute monocytic
leukemia (French-American-British classification M5) does not have
a worse prognosis than other subtypes of acute myeloid leukemia: a
report from the Eastern Cooperative Oncology Group. J Clin Oncol.
22:1276–1286. 2004. View Article : Google Scholar
|
|
6
|
Chen G, Zhang W, Cao X, Li F, Liu X and
Yao L: Serological identification of immunogenic antigens in acute
monocytic leukemia. Leuk Res. 29:503–509. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang PY, Zhang WG, He AL, Wang JL and Li
WB: Identification and functional characterization of the novel
acute monocytic leukemia associated antigen MLAA-34. Cancer Immunol
Immunother. 58:281–290. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhao J, He A, Zhang W, Meng X and Gu L:
Quantitative assessment of MLAA-34 expression in diagnosis and
prognosis of acute monocytic leukemia. Cancer Immunol Immunother.
60:587–597. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lu B, McClatchy DB, Kim JY and Yates JR
III: Strategies for shotgun identification of integral membrane
proteins by tandem mass spectrometry. Proteomics. 8:3947–3955.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
He P, He HZ, Dai J, Wang Y, Sheng QH, Zhou
LP, Zhang ZS, Sun YL, Liu F, Wang K, Zhang JS, Wang HX, Song ZM,
Zhang HR, Zeng R and Zhao X: The human plasma proteome: analysis of
Chinese serum using shotgun strategy. Proteomics. 5:3442–3453.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bowen DT, Frew ME, Hills R, Gale RE,
Wheatley K, Groves MJ, Langabeer SE, Kottaridis PD, Moorman AV,
Burnett AK and Linch DC: RAS mutation in acute myeloid leukemia is
associated with distinct cytogenetic subgroups but does not
influence outcome in patients younger than 60 years. Blood.
106:2113–2119. 2005.PubMed/NCBI
|
|
12
|
Morgan MA, Dolp O and Reuter CW:
Cell-cycle-dependent activation of mitogen-activated protein kinase
kinase (MEK-1/2) in myeloid leukemia cell lines and induction of
growth inhibition and apoptosis by inhibitors of RAS signaling.
Blood. 97:1823–1834. 2001. View Article : Google Scholar
|
|
13
|
Pearn L, Fisher J, Burnett AK and Darley
RL: The role of PKC and PDK1 in monocyte lineage specification by
Ras. Blood. 109:4461–4469. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lay AJ, Jiang XM, Kisker O, Flynn E,
Underwood A, Condron R and Hogg PJ: Phosphoglycerate kinase acts in
tumour angiogenesis as a disulphide reductase. Nature. 408:869–873.
2000. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Valenti MT, Bertoldo F, Dalle Carbonare L,
Azzarello G, Zenari S, Zanatta M, Balducci E, Vinante O and Lo
Cascio V: The effect of bisphosphonates on gene expression: GAPDH
as a housekeeping or a new target gene? BMC Cancer. 6:492006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ullmannová V and Haskovec C: The use of
housekeeping genes (HKG) as an internal control for the detection
of gene expression by quantitative real-time RT-PCR. Folia Biol
(Praha). 49:211–216. 2003.PubMed/NCBI
|
|
17
|
Pan SH, Chao YC, Hung PF, Chen HY, Yang
SC, Chang YL, Wu CT, Chang CC, Wang WL, Chan WK, Wu YY, Che TF,
Wang LK, Lin CY, Lee YC, Kuo ML, Lee CH, Chen JJ, Hong TM and Yang
PC: The ability of LCRMP-1 to promote cancer invasion by enhancing
filopodia formation is antagonized by CRMP-1. J Clin Invest.
121:3189–3205. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Stelzl U, Worm U, Lalowski M, Haenig C,
Brembeck FH, Goehler H, Stroedicke M, Zenkner M, Schoenherr A,
Koeppen S, Timm J, Mintzlaff S, Abraham C, Bock N, Kietzmann S,
Goedde A, Toksöz E, Droege A, Krobitsch S, Korn B, Birchmeier W,
Lehrach H and Wanker EE: A human protein-protein interaction
network: a resource for annotating the proteome. Cell. 122:957–968.
2005.PubMed/NCBI
|
|
19
|
Korherr C, Gille H, Schäfer R,
Koenig-Hoffmann K, Dixelius J, Egland KA, Pastan I and Brinkmann U:
Identification of proangiogenic genes and pathways by
high-throughput functional genomics: TBK1 and the IRF3 pathway.
Proc Natl Acad Sci USA. 103:4240–4245. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Czabanka M, Korherr C, Brinkmann U and
Vajkoczy P: Influence of TBK-1 on tumor angiogenesis and
microvascular inflammation. Front Biosci. 13:7243–7249. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jia ZF, Huang Q, Kang CS, Yang WD, Wang
GX, Yu SZ, Jiang H and Pu PY: Overexpression of septin 7 suppresses
glioma cell growth. J Neurooncol. 98:329–340. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Endo Y, Sugiyama A, Li SA, Ohmori K, Ohata
H, Yoshida Y, Shibuya M, Takei K, Enari M and Taya Y: Regulation of
clathrin-mediated endocytosis by p53. Genes Cells. 13:375–386.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Enari M, Ohmori K, Kitabayashi I and Taya
Y: Requirement of clathrin heavy chain for p53-mediated
transcription. Genes Dev. 20:1087–1099. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ofek P, Ben-Meir D, Kariv-Inbal Z, Oren M
and Lavi S: Cell cycle regulation and p53 activation by protein
phosphatase 2C alpha. J Biol Chem. 278:14299–14305. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Behrend L, Mohr A, Dick T and Zwacka RM:
Manganese superoxide dismutase induces p53-dependent senescence in
colorectal cancer cells. Mol Cell Biol. 25:7758–7769. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shinbo Y, Taira T, Niki T, Iguchi-Ariga SM
and Ariga H: DJ-1 restores p53 transcription activity inhibited by
Topors/p53BP3. Int J Oncol. 26:641–648. 2005.PubMed/NCBI
|
|
27
|
Grover A, Priyandoko D, Gao R, Shandilya
A, Widodo N, Bisaria VS, Kaul SC, Wadhwa R and Sundar D: Withanone
binds to mortalin and abrogates mortalin-p53 complex: Computational
and experimental evidence. Int J Biochem Cell Biol. 44:496–504.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wadhwa R, Yaguchi T, Hasan MK, Mitsui Y,
Reddel RR and Kaul SC: Hsp70 family member, mot-2/mthsp70/GRP75,
binds to the cytoplasmic sequestration domain of the p53 protein.
Exp Cell Res. 274:246–253. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ueno M, Masutani H, Arai RJ, Yamauchi A,
Hirota K, Sakai T, Inamoto T, Yamaoka Y, Yodoi J and Nikaido T:
Thioredoxin-dependent redox regulation of p53-mediated p21
activation. J Biol Chem. 274:35809–35815. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ueda S, Nakamura H, Masutani H, Sasada T,
Yonehara S, Takabayashi A, Yamaoka Y and Yodoi J: Redox regulation
of caspase-3(-like) protease activity: regulatory roles of
thioredoxin and cytochrome c. J Immunol. 161:6689–6695.
1998.PubMed/NCBI
|
|
31
|
Hsu HH, Cheng SF, Chen LM, Liu JY, Chu CH,
Weng YJ, Li ZY, Lin CS, Lee SD, Kuo WW and Huang CY: Over-expressed
estrogen receptor-α upregulates hTNF-α gene expression and
downregulates β-catenin signaling activity to induce the apoptosis
and inhibit proliferation of LoVo colon cancer cells. Mol Cell
Biochem. 289:101–109. 2006.
|
|
32
|
Kouzmenko AP, Takeyama K, Ito S, Furutani
T, Sawatsubashi S, Maki A, Suzuki E, Kawasaki Y, Akiyama T, Tabata
T and Kato S: Wnt/β-catenin and estrogen signaling converge in
vivo. J Biol Chem. 279:40255–40258. 2004.
|
|
33
|
Won J, Kim DY, La M, Kim D, Meadows GG and
Joe CO: Cleavage of 14–3–3 protein by caspase-3 facilitates bad
interaction with Bcl-x(L) during apoptosis. J Biol Chem.
278:19347–19351. 2003.
|
|
34
|
Vousden KH and Prives C: P53 and
prognosis: new insights and further complexity. Cell. 120:7–10.
2005.PubMed/NCBI
|
|
35
|
Vousden KH and Lane DP: p53 in health and
disease. Nat Rev Mol Cell Biol. 8:275–283. 2007. View Article : Google Scholar
|
|
36
|
Pietsch EC, Sykes SM, McMahon SB and
Murphy ME: The p53 family and programmed cell death. Oncogene.
27:6507–6521. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kruse JP and Gu W: Modes of p53
regulation. Cell. 137:609–622. 2009. View Article : Google Scholar
|
|
38
|
Plosker GL and Figgitt DP: Rituximab: a
review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic
leukaemia. Drugs. 63:803–843. 2003.
|
|
39
|
Gavin AC, Bösche M, Krause R, Grandi P,
Marzioch M, Bauer A, Schultz J, Rick JM, Michon AM, Cruciat CM,
Remor M, Höfert C, Schelder M, Brajenovic M, Ruffner H, Merino A,
Klein K, Hudak M, Dickson D, Rudi T, Gnau V, Bauch A, Bastuck S,
Huhse B, Leutwein C, Heurtier MA, Copley RR, Edelmann A, Querfurth
E, Rybin V, Drewes G, Raida M, Bouwmeester T, Bork P, Seraphin B,
Kuster B, Neubauer G and Superti-Furga G: Functional organization
of the yeast proteome by systematic analysis of protein complexes.
Nature. 415:141–147. 2002. View
Article : Google Scholar : PubMed/NCBI
|
